BBOT vs MGM · rev $7.5M vs P/E 64, rev $4.45B
BridgeBio Oncology Therapeutics, Inc. (BBOT) versus MGM Resorts International (MGM) — a side-by-side from cached financials, not a winner call.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.
MGM Resorts International (MGM) is a resorts & casinos company listed on NYSE.
Latest reported BBOT revenue for 2026-06-30 was $7.5M. Net income was -$98.6M. Revenue was up 90.0% from 2026-03-31 to 2026-06-30. BBOT currently screens at market cap $610.4M.
Latest reported MGM revenue for 2026-06-30 was $4.45B. Net income was $292.4M. Revenue was down 0.1% from 2026-03-31 to 2026-06-30. MGM currently screens at market cap $12.01B and trailing P/E 64.3.
BBOT currently screens at market cap $610.4M. MGM currently screens at market cap $12.01B and trailing P/E 64.3.
Not investment advice. Open the BBOT and MGM stock pages for the full models.
Not investment advice.